Trial Profile

A study of KRIYA 586 for Thyroid Eye Disease (TED)

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 06 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs KRIYA 586 (Primary)
Indications Graves ophthalmopathy
Focus Adverse reactions

Most Recent Events

29 Apr 2025 According to Kriya Therapeutics media release, the data from this study will be presented at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, which will be held May 13 to 17, 2025 in New Orleans, LA
15 Jan 2024 New trial record
05 Jan 2024 According to Kriya Therapeutics media release, trial will be initiate in 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com